Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial
在既往未接受治疗的慢性淋巴细胞白血病或小淋巴细胞淋巴瘤患者中，因微小残留病灶而停药的Zanubrutinib、obinutuzumab和venetoclax联合治疗：一项多中心、单臂II期试验
期刊:Lancet Haematology
影响因子:17.7
doi:10.1016/S2352-3026(21)00307-0
Soumerai, Jacob D; Mato, Anthony R; Dogan, Ahmet; Seshan, Venkatraman E; Joffe, Erel; Flaherty, Kelsey; Carter, Jason; Hochberg, Ephraim; Barnes, Jeffrey A; Hamilton, Audrey M; Abramson, Jeremy S; Batlevi, Connie L; Matasar, Matthew J; Noy, Ariela; Owens, Colette N; Palomba, M Lia; Kumar, Anita; Takvorian, Tak; Ni, Ai; Choma, Morgan; Friedman, Chaya; Chadha, Puja; Simkins, Elizabeth; Ruiters, Jade; Sechio, Sidney; Portman, Daneal; Ramos, Lauren; Nolet, Natascha; Mahajan, Neena; Martignetti, Rosalba; Mi, Joanna; Scorsune, Krista; Lynch, Julia; McGree, Brianne; Hughes, Stephanie; Grieve, Clare; Roeker, Lindsey E; Thompson, Meghan; Johnson, P Connor; Roshal, Mikhail; Huang, Jane; Biondo, Juliana; Wu, Qun; Jacob, Allison; Abdel-Wahab, Omar; Zelenetz, Andrew D
